R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
2009 AUG 3 - (NewsRx.com) -- R-Tech Ueno, Ltd. announced on July 17 that as a phase 1 clinical study on the new compound RK-023 that is being developed by our company as a therapeutic drug of androgenetic alopecia (male pattern baldness; see the note below) has been completed. The phase 1 clinical study of RK-023 consisted of a patch test (open, closed, photo-patch test), single-dose study and 5-day repeated-dose study. Since no serious adverse event occurred in each test, RK-023 seems to hardly cause any safety problem in the human body. As the first step, patch tests were conducted to obtain data on skin irritation. Using RK-023 preparation and a placebo, the tests were conducted on 20 healthy adult males by the following 3 methods and the results were evaluated. (1) Open patch test: Open patch dressing to the forearm skin for 48 hours (2) Closed patch test: Closed patch dressing to the back skin for 48 hours (3) Photo-patch test: Closed patch dressing to the back skin for 24 hours, Keywords: Adverse Drug Effect, Adverse Drug Event, Adverse Drug Reaction, Alopecia, Clinical Trial Research, Therapy, Treatment, R-Tech Ueno Ltd. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
